Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Ide Y, Otsuka T, Shimokawa M, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T. Ide Y, et al. Among authors: shinohara y. Anticancer Res. 2023 Apr;43(4):1817-1826. doi: 10.21873/anticanres.16335. Anticancer Res. 2023. PMID: 36974805
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, Uchino K, Shirakawa T, Shibata Y, Shinohara Y, Inadomi K, Tsuchihashi K, Arita S, Ariyama H, Esaki T, Akashi K, Baba E. Takayoshi K, et al. Among authors: shinohara y. Cancer Chemother Pharmacol. 2017 Aug;80(2):333-342. doi: 10.1007/s00280-017-3371-0. Epub 2017 Jun 26. Cancer Chemother Pharmacol. 2017. PMID: 28653251 Free article.
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T, Ohmura H, Komoda M, Uchino K, Inadomi K, Arita S, Ariyama H, Kusaba H, Shinohara Y, Kuwayama M, Kajitani T, Oda H, Esaki T, Akashi K, Baba E. Makiyama A, et al. Among authors: shinohara y. Gastric Cancer. 2018 May;21(3):464-472. doi: 10.1007/s10120-017-0759-9. Epub 2017 Aug 10. Gastric Cancer. 2018. PMID: 28799048
Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Tanoue K, Tamura S, Kusaba H, Shinohara Y, Ito M, Tsuchihashi K, Shirakawa T, Otsuka T, Ohmura H, Isobe T, Ariyama H, Koreishi S, Matsushita Y, Shimokawa H, Tanaka R, Mitsugi K, Akashi K, Baba E. Tanoue K, et al. Among authors: shinohara y. Sci Rep. 2021 Feb 2;11(1):2741. doi: 10.1038/s41598-021-82448-1. Sci Rep. 2021. PMID: 33531609 Free PMC article.
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: shinohara y. Sci Rep. 2023 May 31;13(1):8815. doi: 10.1038/s41598-023-34962-7. Sci Rep. 2023. PMID: 37258608 Free PMC article.
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: shinohara y. Sci Rep. 2024 Mar 4;14(1):5311. doi: 10.1038/s41598-024-55673-7. Sci Rep. 2024. PMID: 38438505 Free PMC article. No abstract available.
Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin.
Tsuchihashi K, Kusaba H, Yoshihiro T, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Imajima T, Shinohara Y, Ito M, Yamaga S, Tanoue K, Arimizu K, Ohmura H, Hanamura F, Yamaguchi K, Isobe T, Ariyama H, Nakashima Y, Akashi K, Baba E. Tsuchihashi K, et al. Among authors: shinohara y. Sci Rep. 2020 Dec 1;10(1):20896. doi: 10.1038/s41598-020-77898-y. Sci Rep. 2020. PMID: 33262403 Free PMC article.
A case of community-acquired Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus (MRSA) necrotizing pneumonia successfully treated with two anti-MRSA drugs.
Shiiba R, Sano M, Kogure Y, Murao H, Takigawa Y, Torii A, Yamada A, Shinohara Y, Niwa H, Kitagawa C, Oki M. Shiiba R, et al. Among authors: shinohara y. Respir Med Case Rep. 2024 Apr 18;49:102023. doi: 10.1016/j.rmcr.2024.102023. eCollection 2024. Respir Med Case Rep. 2024. PMID: 38681212 Free PMC article.
Histological evaluation of nonsurgical periodontal treatment with and without the use of sodium hypochlorite / amino acids and cross-linked hyaluronic acid gels in dogs.
Shirakata Y, Nakamura T, Setoguchi F, Imafuji T, Shinohara Y, Matsumura S, Iwata M, Noguchi K, Ramanauskaite E, Sculean A. Shirakata Y, et al. Among authors: shinohara y. Clin Oral Investig. 2024 Apr 27;28(5):281. doi: 10.1007/s00784-024-05674-7. Clin Oral Investig. 2024. PMID: 38676852 Free PMC article.
1,323 results